What's in PT Bio Farma's pipeline?

PT Bio Farma has 20 drugs in our index: 7 marketed, 0 filed, 5 in Phase 3, 8 in Phase 2, 0 in Phase 1.

Which companies overlap with PT Bio Farma's portfolio?

Top competitors by shared drug class: Sanofi Pasteur, a Sanofi Company, Merck Sharp & Dohme LLC, GlaxoSmithKline, PATH, Jiangsu Province Centers for Disease Control and Prevention.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pt-bio-farma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

PT Bio Farma — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PT Bio Farma pipeline: 7 marketed, 0 filed, 5 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 5 Phase 3 8 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
SARS-CoV-2 Inactivated Vaccine	SARS-CoV-2 Inactivated Vaccine	marketed	Inactivated viral vaccine		Immunology / Infectious Disease
Diphtheria Antitoxin	Diphtheria Antitoxin	marketed	Antitoxin (passive immunotherapy)	Diphtheria toxin	Infectious Disease
Pentavalen	Pentavalen	marketed			Other
Pentabio	Pentabio	marketed			Other
Influenzae vaccine	Influenzae vaccine	marketed
Active Comparator	Active Comparator	marketed	SSRI		Psychiatry
Measles-Rubella (MR) Vaccine	Measles-Rubella (MR) Vaccine	marketed	Live attenuated viral vaccine		Immunology / Infectious Disease
Hep B + Pentabio (registered)	Hep B + Pentabio (registered)	phase 3	Combination vaccine		Immunology / Infectious Disease Prevention
PQed Typhoid Conjugate Vaccine	PQed Typhoid Conjugate Vaccine	phase 3	Conjugate vaccine	Salmonella typhi polysaccharide antigen	Immunology / Infectious Disease
Recombinant Hepatitis B + DTP-HB-Hib	Recombinant Hepatitis B + DTP-HB-Hib	phase 3	Combination vaccine		Immunology / Infectious Disease
Vi-DT Typhoid Conjugate Vaccine	Vi-DT Typhoid Conjugate Vaccine	phase 3	Conjugate vaccine		Immunology
Vi Polysaccharide Vaccine	Vi Polysaccharide Vaccine	phase 3

Therapeutic area mix

Immunology / Infectious Disease · 4
Immunology · 2
Infectious Disease · 2
Other · 2
Immunology / Infectious Disease Prevention · 1
Psychiatry · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi Pasteur, a Sanofi Company · 5 shared drug classes
Merck Sharp & Dohme LLC · 5 shared drug classes
GlaxoSmithKline · 5 shared drug classes
PATH · 4 shared drug classes
Jiangsu Province Centers for Disease Control and Prevention · 4 shared drug classes
Sanofi · 4 shared drug classes
Institute of Medical Biology, Chinese Academy of Medical Sciences · 3 shared drug classes
Novartis · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for PT Bio Farma:

Cite this brief

Drug Landscape (2026). PT Bio Farma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pt-bio-farma. Accessed 2026-05-16.